Recent Posts
- Real-World Experience with Rezafungin: A Novel Long-Acting Echinocandin
- Immune Globulin Subcutaneous 16.5% in Immunoglobulin-Naïve Patients with Primary Immunodeficiency
- Effectiveness of A Community-based Inflammatory Bowel Disease Medical Home Compared to Patients not in a Medical Home
- Real-world Effectiveness and Onset of Action of Vedolizumab as a First-line Biologic in Biologic-Naïve Patients With Ulcerative Colitis
- Immune Globulin Subcutaneous 16.5% in Treatment of Primary Immunodeficiency: A Two-Year, Multi-Center Analysis
Archives
- April 2025
- March 2025
- February 2025
- December 2024
- October 2024
- August 2024
- May 2024
- April 2024
- February 2024
- November 2023
- October 2023
- June 2023
- February 2023
- January 2023
- November 2022
- October 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- November 2021
- October 2021
- September 2021
- November 2020
- October 2020
- July 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- October 2019
- August 2019
- July 2019
- May 2019
- April 2019
- February 2019
- December 2018
- October 2018
- July 2018
- June 2018
- January 2018
- December 2017
- October 2017
- July 2017
- June 2017
- March 2017
- October 2016
- June 2016
- January 2016
- October 2015
- December 2014
- October 2014
- November 2013
- October 2013
- July 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- April 2012
- February 2012
- January 2012
- October 2011
- January 2011
- October 2010
- October 2009
- October 2008
Recent Comments